The potential role of topical valproate (VPA) in hair regrowth has been recently suggested. However, safety reports of VPA as a topical formulation are lacking. Therefore, in the present study, we investigated whether VPA causes skin irritation in humans. We first performed a cell viability test and showed that VPA did not exhibit toxicity toward HaCaT keratinocytes, fibroblasts, and RBL-3H mast cells. We then performed clinical patch test and skin irritation test through transdermal drug delivery with the help of microneedle rollers. No significant findings were obtained in the clinical patch test. In the skin irritation test, only 1 patient showed erythema at 1 hr, but the irritation reaction faded away within a few hours. Erythema and edema were not observed at 24 hr. We concluded that VPA has minimal potential to elicit skin irritation. Therefore, we consider that VPA can safely be applied to human skin.
INTRODUCTION
Valproic acid (VPA) is a mood stabilizer that has been commonly prescribed for the treatment of epilepsy and bipolar disorder over the last several decades (1) . Antiepileptic drugs including VPA frequently cause cutaneous eruptions, especially during initiation of new therapy. In addition to causing common and usually limited morbilliform and urticarial eruptions, which have often mild morbidity, antiepileptic drugs can also induce widespread maculopapular rash, hypersensitivity syndrome, psoriatic dermatitis and occasionally severe reactions such as Steven Johnson's syndrome, toxic epidermal necrolysis and erythema multiforme (2, 3) .
In recent studies using animal models, topical application of VPA stimulated hair re-growth (4) . In an in vitro study, VPA up-regulated the Wnt/β-catenin pathway and alkaline phosphatase activity in human dermal papilla cells (4) .
Activation of the Wnt/β-catenin pathway is required for initiation of hair follicle formation (5), and stimulates growth and differentiation of hair by maintaining expression of genes that function at the anagen phase of the hair cycle (6). Consequently, it was suggested that VPA could be developed as a topical drug to stimulate hair re-growth (4), but there are currently no studies on the safety of VPA for skin application. The aim of the present study was to investigate whether VPA exhibits toxicity towards skin. We tested the toxicity of VPA in keratinocytes, fibroblasts and mast cells and performed skin tests in healthy human subjects using a clinical patch test and skin irritation tests through transdermal drug delivery using microneedle rollers.
MATERIALS AND METHODS

Materials.
Twenty healthy volunteers aged 21 to 43 years (mean age 30.4) were enrolled for primary skin irritation and toxicity tests. Individuals were excluded if they had current or past history of underlying chronic skin diseases that might interfere with the evaluation of skin reactions. We used sodium valproate (95 mg/ml) and normal saline (as a negative control) for skin tests.
The study was approved by the relevant institutional review boards. All subjects signed informed consent forms, and the study protocol conformed to the guidelines set forth by the Declaration of Helsinki and Korean Good Clinical 
Clinical patch test.
A patch test was performed on the skin of all subjects. The test samples (0.2 ml of VPA or normal saline) were placed in a Finn Chamber (Chemotechnique Diagnostics, Sweden) and applied to the ventral side of the upper arm of each subject for 48 hrs in an occlusive condition. Skin reactions were evaluated at 1 hr and 48 hrs after removing the test samples. The reaction was evaluated according to the International Contact Dermatitis Research Group (ISDRG) standard (Table 1) (7).
Skin irritation test.
The skin irritation test was performed on three skin test sites of all subjects: frontal scalp, upper arm and upper back. We used the method of transdermal drug delivery by microneedle rollers to perform the skin irritation test. The microneedle rollers used in this study were supplied by DTS Lab Inc. (Disk Microneedles Therapy System Lab, Inc., Seoul, South Korea). The microneedle roller was 0.25 mm long and had 60 circular arrays of nine needles each (a total of 540 needles) in a cylindrical assembly (20-mm diameter, 18.2-mm length). The test samples (2.0 ml of VPA or normal saline) were applied to a 2 cm × 4 cm area of each test site and the microneedle roller was rolled four times on the skin test sites. Skin irritation test sites were examined for the presence of erythema and edema according to the dermal irritation scoring system (Table 2) at 1 hr and 24 hrs (8) .
RESULTS AND DISCUSSION
We performed cell viability tests for VPA in HaCaT keratinocytes, fibroblasts, and RBL-3H mast cells. After treatment with various concentrations of VPA, cell toxicity was not observed in RBL-2H3, HaCaT or fibroblast cells (Fig. 1) .
We next performed a clinical patch test on 20 healthy volunteers. No significant clinical findings were observed at 1 hr and 48 hrs after removing the test samples. A skin irri- (Table 3 ). The time course of recovery from irritation is depicted in Fig. 2 . Erythema faded away quickly and the skin returned to normal within a short period. In our study, the skin irritation test was performed not by simple application, but by transdermal drug delivery using 
